• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » What keeps you up at night? Obstacles and opportunities in med-tech at the MassDevice Big 100 Regional Roundtable

What keeps you up at night? Obstacles and opportunities in med-tech at the MassDevice Big 100 Regional Roundtable

July 12, 2011 By Gretchen Baker

Jeffrey Shuren
FDA CDRH chief Dr. Jeffrey Shuren addresses the
audience in a live Q&A

Hundreds of representatives from New England’s medical device industry gathered last night at the MassDevice Big 100 Regional Roundtable at the Westin Hotel in Waltham, Mass., to share their experiences and ideas for the industry’s future.

The event took off with a live Q&A with Dr. Jeffrey Shuren, director of the FDA’s Center for Devices & Radiological Health. In a lengthy Q&A session with the more than 250 attendees, Shuren answered questions and detailed the obstacles his agency faces in workforce turnover and employee inexperience.

He also explained an FDA pilot program with the Centers for Medicare and Medicaid Services aimed at facilitating “parallel review” of devices by the federal watchdog and reimbursement agencies.

"It’s not changing FDA standards," Shuren explained. The purpose of the parallel review is to "shave some time of" of the time it takes to get a device reviewed by the CDRH and to win reimbursement from CMS.

Shuren also tackled the problem of unpredictability in pre-market reviews, saying that FDA has evaluated the 510(k) process and how the industry uses science to identify speedier ways to review devices. Last summer the agency outlined 25 actions necessary for improvement of the PMA process.

Big 100 Regional Roundtable

Shuren insisted that innovation is a high priority at the CDRH and that the agency will be more responsive to industry concerns. Regarding clinical evidence requirements for 510(k) applications, Shuren said that only about 10 percent of 510(k) submissions need clinical data.

"All we are seeking to do is to provide better clarity on the circumstances of when we would ask for clinical data," he said. Asked about the agency’s accomplishments and what it still has on its plate, Shuren said there have been some signal accomplishments but that, "We have a ways to go."

"Our top achievement is the fact that we have put innovation high on our list of priorities," Shuren said, noting reforms including reducing time of development — which in turn reduces costs — and better tools, including computer models that can potentially reduce the need for animal testing or early human studies.

After Shuren left to catch a flight back to Washington, the evening’s keynote event began. Joe Almeida, the newly minted president & CEO of Covidien plc (NYSE:COV), in a candid, one-on-one interview with MassDevice publisher Brian Johnson, said that successful businesses are, by definition, ethical businesses.

"Big egos don’t have a place in business," noted Almeida, who said he never imagined he’d be at the helm of a billion-dollar organization. His aspirations, he said, once only reached as high as VP of operations.

Joe Almeida and MassDevice publisher Brian Johnson

Almeida and MassDevice publisher Brian Johnson

Almeida also spoke of the pressure to balance shareholder value and innovation.

"What we represent for our customer has evolved," he said, emphasizing the importance of compassion and clinical value in maintaining Covidien’s brand. "Customers need to be happy for the shareholder to be happy."

The evening ended with a roundtable discussion among four life science industry CEOs, moderated by MassDevice executive editor Brad Perriello, on the challenges and opportunities facing their various industries.

Richard Packer, CEO of ZOLL Medical Corp. (NSDQ:ZOLL); Don Hardison, CEO of Good Start Genetics; Scott Rader, CEO of IlluminOss Medical Inc.; and David Lucchino, CEO of Semprus Biosciences discussed the challenges of winning reimbursement for preventive care, the value of physician collaboration in designing products and maintaining an ethical standard for marketing, even in a slow economy.

CEO Panel

"Prove the benefit of the product, then take it to the market," said Rader, urging the crowd of medical device executives to make sure their marketing practices are cleaner, better and faster. "Doing it right is the challenge of the entrepreneur."

Filed Under: 510(k), Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA) Tagged With: Covidien, Good Start Genetics Inc., IlluminOss Medical Inc., MassDevice Big 100 Regional Roundtable, MassDevice Q&A, MassDevice.com, Semprus BioSciences, Zoll Medical

More recent news

  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy